The Biden administration on Friday announced an agreement to purchase 100,000 doses of Eli Lilly’s monoclonal antibody cocktail that was recently authorized by the Food and Drug Administration (FDA).

The move will increase the available supply of one of the few proven treatments for people with COVID-19. The antibody drugs are authorized for use in patients who are at high risk of becoming seriously ill but are not yet hospitalized.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

Under the agreement, the federal government will pay $210 million for the initial purchase of up to 100,000 treatment courses of the therapeutic, which is a combination of the drug bamlanivimab, which was authorized last November for high-risk COVID-19 patients, with a second drug known as etesevimab.

The combination received emergency use authorization earlier this month, after data showed it reduced the risk of hospitalization and death by 70 percent.

Read more at The Hill.